JP4637356B2 - 広い反応性の中和抗体応答を伴うhiv−1エンベロープタンパク質の発現およびキャクタライゼーション - Google Patents

広い反応性の中和抗体応答を伴うhiv−1エンベロープタンパク質の発現およびキャクタライゼーション Download PDF

Info

Publication number
JP4637356B2
JP4637356B2 JP2000563313A JP2000563313A JP4637356B2 JP 4637356 B2 JP4637356 B2 JP 4637356B2 JP 2000563313 A JP2000563313 A JP 2000563313A JP 2000563313 A JP2000563313 A JP 2000563313A JP 4637356 B2 JP4637356 B2 JP 4637356B2
Authority
JP
Japan
Prior art keywords
hiv
envelope protein
hiv envelope
sequence
neutralization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000563313A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002522039A (ja
JP2002522039A5 (cg-RX-API-DMAC7.html
Inventor
ジェラルド, ヴィ., ジュニア キーナン,
ペン, フェイ ツァン,
Original Assignee
ザ ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド filed Critical ザ ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド
Publication of JP2002522039A publication Critical patent/JP2002522039A/ja
Publication of JP2002522039A5 publication Critical patent/JP2002522039A5/ja
Application granted granted Critical
Publication of JP4637356B2 publication Critical patent/JP4637356B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2000563313A 1998-08-04 1999-08-04 広い反応性の中和抗体応答を伴うhiv−1エンベロープタンパク質の発現およびキャクタライゼーション Expired - Fee Related JP4637356B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9526798P 1998-08-04 1998-08-04
US60/095,267 1998-08-04
PCT/US1999/017596 WO2000007631A1 (en) 1998-08-04 1999-08-04 Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response

Publications (3)

Publication Number Publication Date
JP2002522039A JP2002522039A (ja) 2002-07-23
JP2002522039A5 JP2002522039A5 (cg-RX-API-DMAC7.html) 2010-01-28
JP4637356B2 true JP4637356B2 (ja) 2011-02-23

Family

ID=22251048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000563313A Expired - Fee Related JP4637356B2 (ja) 1998-08-04 1999-08-04 広い反応性の中和抗体応答を伴うhiv−1エンベロープタンパク質の発現およびキャクタライゼーション

Country Status (7)

Country Link
EP (1) EP1104310B1 (cg-RX-API-DMAC7.html)
JP (1) JP4637356B2 (cg-RX-API-DMAC7.html)
AT (1) ATE435034T1 (cg-RX-API-DMAC7.html)
AU (1) AU762376C (cg-RX-API-DMAC7.html)
CA (1) CA2338886C (cg-RX-API-DMAC7.html)
DE (1) DE69941051D1 (cg-RX-API-DMAC7.html)
WO (1) WO2000007631A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW511388B (en) 2000-03-28 2002-11-21 Koninkl Philips Electronics Nv Passive radiator having mass elements
US20080057492A1 (en) * 2002-05-10 2008-03-06 Quinnan Jr Gerald V Interacting site for gp41 on gp120 of hiv-1
ES2385481T3 (es) * 2003-06-20 2012-07-25 Siemens Healthcare Diagnostics Products Gmbh Nueva variante de proteína de superficie (HbsAg) del virus de hepatitis B
US7485312B2 (en) 2003-06-20 2009-02-03 Dade Behring Marburg Gmbh Surface protein (HBsAg) variant of the hepatitis B virus
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP2013227A4 (en) * 2006-05-09 2010-07-28 Jackson H M Found Military Med HIV-1 immunostained compositions
CA2705373A1 (en) * 2007-11-12 2009-08-20 The Henry M. Jackson Foundation For The Advancement Of Military Medicine , Inc. Hiv-1 envelope glycoprotein oligomer and methods of use
MX2012011189A (es) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Vacuna contra el virus e inmunodeficiencia humana.
WO2012041842A1 (en) 2010-09-27 2012-04-05 Glaxosmithkline Biologicals S.A. Vaccine
EP2892554B1 (en) 2012-09-07 2020-08-26 Emory University Hiv immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820865A (en) * 1988-01-26 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
WO1992020373A1 (en) * 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE570357T1 (de) * 1992-05-14 1994-07-28 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.
GB9318901D0 (en) * 1993-09-13 1993-10-27 Centre Nat Rech Scient Multiple branch peptide construction

Also Published As

Publication number Publication date
AU762376C (en) 2004-10-14
EP1104310A4 (en) 2003-01-08
JP2002522039A (ja) 2002-07-23
AU5464299A (en) 2000-02-28
CA2338886A1 (en) 2000-02-17
DE69941051D1 (de) 2009-08-13
EP1104310A1 (en) 2001-06-06
AU762376B2 (en) 2003-06-26
CA2338886C (en) 2011-10-04
WO2000007631A1 (en) 2000-02-17
WO2000007631A9 (en) 2000-11-16
EP1104310B1 (en) 2009-07-01
ATE435034T1 (de) 2009-07-15

Similar Documents

Publication Publication Date Title
JP3967374B2 (ja) 同調的インビボ遺伝子発現
AU729231B2 (en) Synthetic HIV genes
AP1282A (en) HIV envelope polypeptides and vaccine.
US20030229214A1 (en) Vaccines comprising synthetic genes
CA2258568A1 (en) Vaccines comprising synthetic genes
US20110014221A1 (en) Hiv combination vaccine and prime boost
US6585979B1 (en) HIV envelope polypeptides and immunogenic composition
EP1104310B1 (en) Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
US20070166784A1 (en) Combination approaches for generating immune responses
US20100015211A1 (en) Combination Approaches For Generating Immune Responses
US20100080818A1 (en) Expression and Characterization of HIV-1 Envelope Protein Associated with Broadly Cross Reactive Neutralizing Antibody Response
JP5290576B2 (ja) 修飾されたhiv−1エンベロープタンパク質
AU2003299489B2 (en) Interacting site for gp41 on gp120 of HIV-1
Barrett et al. Vaccines in AIDS: present state of knowledge
US20030087225A1 (en) Synthetic HIV genes
ZA200603029B (en) Combination approaches for generating immune responses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091111

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20091204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100624

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101026

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101124

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131203

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees